Petros Pharmaceuticals, Inc., a company focused on expanding consumer access to medications, is developing a first-of-its-kind SaaS platform to facilitate the switch of prescription drugs to over-the-counter (OTC) status. The company, listed on NASDAQ (PTPI), announced this significant strategic move on May 1, 2025, in response to President Trump’s recent Executive Order aimed at enhancing access to medicines through OTC approvals under the Make America Healthy Again (MAHA) initiative. Petros’ new platform is designed to integrate key cloud-based technologies, including artificial intelligence (AI), electronic health records (EHRs), and robust cybersecurity measures, to provide pharmaceutical companies with a comprehensive and licensable solution. The platform aims to comply with the FDA’s Additional Conditions for Nonprescription Use (ACNU) guidelines, which are intended to streamline the process of transitioning prescription drugs to OTC status. By adhering to these guidelines, the platform will help ensure that consumers can accurately self-select appropriate OTC medications and use them safely. The SaaS platform will offer services such as patient self-selection tools, EHR integration to support safe usage, and potential integration with retail pharmacies. It will work alongside Petros’ existing Software as a Medical Device (SaMD) web application, which serves as the consumer-facing interface for various therapeutic needs. Petros identifies several conditions that could benefit from an Rx-to-OTC switch, including erectile dysfunction, hypercholesterolemia, migraines, anxiety, and urinary tract infections. President and Chief Commercial Officer, Fady Boctor, emphasized the strategic importance of this shift. He stated, "We believe this significant move in our business strategy may fill an important role as many blockbuster drugs and their manufacturers face critical lifecycle management decisions. This initiative aligns with President Trump’s Executive Order, which underscores the need to create more pathways for expanded access to pharmaceutical products to help control rising healthcare costs. The expansion of access is crucial, and we are confident that our SaaS program will address longstanding challenges such as retail integration, EHR interoperability, and commercial scalability." The self-care market, currently valued at over $38 billion, is projected to grow at a compound annual rate of 5.6% over the next decade. Petros’ platform is informed by extensive research, including 28 completed studies focusing on label comprehension and self-selection, ensuring it meets the FDA’s stringent requirements for consumer safety and understanding. To achieve an Rx-to-OTC switch, the FDA mandates a series of tests and evaluations. These include iterative Label Comprehension Studies (LCS) to ensure consumers understand the Drug Facts Label (DFL), Self-Selection Studies (SSS) to confirm consumers can make informed decisions about using the product, and Actual Use Trials (AUT) to demonstrate safe and effective use in a simulated OTC setting. ACNU criteria, which can involve innovative computerized tools, aim to facilitate correct self-selection and broader OTC access. Petros Pharmaceuticals aims to become a leader in the self-care market by leveraging its proprietary technology to assist pharmaceutical companies in navigating the complex regulatory landscape and extending the commercial viability of their products. The company’s integrated approach, combining SaaS and SaMD, represents a significant step forward in addressing the growing demand for accessible and cost-effective healthcare solutions. Industry insiders view this development positively, highlighting the potential for Petros to revolutionize the Rx-to-OTC switch process. The company’s deep understanding of the regulatory requirements and its commitment to robust technology and research could pave the way for more efficient and safer transitions of prescription drugs to OTC status, ultimately benefiting both consumers and pharmaceutical companies. With a strong focus on innovation and compliance, Petros is well-positioned to capture a significant share of the rapidly growing self-care market. Petros Pharmaceuticals, Inc. is a leading innovator in the self-care market, committed to developing technologies that expand consumer access to key prescription pharmaceuticals as OTC treatment options. The company’s strategic development of its SaaS and SaMD platforms is designed to meet rigorous FDA standards and support the MAHA initiative, positioning Petros as a pivotal player in the future of healthcare technology.